Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260)

L. M Demeter; R. W Shafer; P. M Meehan; J Holden-Wiltse; M. A Fischl; W. W Freimuth; M. F Para; R. C Reichman

doi:10.1128/AAC.44.3.794-797.2000

Back

Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260)

Journal article

Open access

Peer reviewed

Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260)

L. M Demeter, R. W Shafer, P. M Meehan, J Holden-Wiltse, M. A Fischl, W. W Freimuth, M. F Para and R. C Reichman

Antimicrobial agents and chemotherapy, Vol.44(3), pp.794-797

Note

2000-03

DOI: https://doi.org/10.1128/AAC.44.3.794-797.2000

PMCID: PMC89771

PMID: 10681363

Abstract

Antiviral Agents

The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominant reverse transcriptase mutations. P236L, which confers DLV resistance but hypersensitivity to other NNRTIs, developed in <10% of isolates.

Files and links (1)

url

https://doi.org/10.1128/AAC.44.3.794-797.2000View

Published (Version of record) Open

Metrics

6 Record Views

69 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Industry collaboration; Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.66 HIV; 1.66.762 Nucleosides
Web Of Science research areas: Microbiology; Pharmacology & Pharmacy
ESI research areas: Pharmacology & Toxicology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260)
Creators: L. M Demeter - University of Rochester School of Medicine and Dentistry, Rochester, New York
R. W Shafer - University of Rochester School of Medicine and Dentistry, Rochester, New York
P. M Meehan - University of Rochester School of Medicine and Dentistry, Rochester, New York
J Holden-Wiltse - University of Rochester School of Medicine and Dentistry, Rochester, New York
M. A Fischl - University of Rochester School of Medicine and Dentistry, Rochester, New York
W. W Freimuth - University of Rochester School of Medicine and Dentistry, Rochester, New York
M. F Para - University of Rochester School of Medicine and Dentistry, Rochester, New York
R. C Reichman - University of Rochester School of Medicine and Dentistry, Rochester, New York
Publication Details: Antimicrobial agents and chemotherapy, Vol.44(3), pp.794-797
Series: Note
Publisher: American Society for Microbiology
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Infectious Diseases
Language: English
Resource Type: Journal article
PMID: 10681363
PMCID: PMC89771
Record Identifier: 991031578022802976